$TLPH News

Last published 2mo ago

2mo agoTLPHTalphera to Participate in the H.C. Wainwright 28th Annual Global Investment ConferencePR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
3mo agoTLPHTalphera Announces Second Quarter 2026 Financial Results and Provides Corporate UpdatePR NewswireNEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this yearDraft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from previous
3mo agoTLPHTalphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026PR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
6mo agoTLPHTalphera Announces First Quarter 2026 Financial Results and Provides Corporate UpdatePR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
6mo agoTLPHTalphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026PR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
7mo agoTLPHTalphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026PR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
7mo agoTLPHTalphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdatePR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
7mo agoTLPHTalphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026PR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
8mo agoTLPHTalphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational TrialPR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
12mo agoTLPH CRMDTalphera Announces Third Quarter 2025 Financial Results and Provides Corporate UpdatePR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
1y agoTLPHTalphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025PR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
1y agoTLPH CRMDTalphera Announces the Appointment of Joe Todisco to Board of DirectorsPR NewswireTalphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative...
1y agoCRMD TLPHCorMedix Announces Strategic Minority Investment in TalpheraGlobeNewswireBERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. ("CorMedix") (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening
1y agoTLPH CRMDTalphera Announces Private Placement Financing of up to $29 Million Priced At-the MarketPR NewswireTalphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative...
1y agoTLPHTalphera Announces Achievement of 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal TrialPR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
1y agoTLPHTalphera, Inc. (TLPH) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
1y agoTLPHTalphera Announces Second Quarter 2025 Financial Results and Provides Corporate UpdatePR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
1y agoTLPHTalphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025PR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
1y agoTLPHTalphera Announces First Quarter 2025 Financial Results and Provides Corporate UpdatePR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
1y agoTLPHTalphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025PR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
1y agoTLPHTalphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdatePR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
1y agoTLPHTalphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 MillionPR NewswireTalphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative...
1y agoTLPHTalphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025PR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
1y agoTLPHTalphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT StudyPR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
1y agoTLPH OLMA SYNACT MGTX+1Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive DirectorsPR NewswireAscentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global...
1y agoTLPHTalphera, Inc. (TLPH) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
1y agoTLPHTalphera Announces Third Quarter 2024 Financial Results and Provides Corporate UpdatePR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
2y agoTLPHTalphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024PR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
2y agoTLPHTalphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual SummitPR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
2y agoTLPHTalphera to Participate in the H.C. Wainwright 26th Annual Global Investment ConferencePR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
2y agoTLPHTalphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal CircuitPR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
2y agoTLPHTalphera, Inc. (TLPH) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoTLPHTalphera Announces Second Quarter 2024 Financial Results and Provides Corporate UpdatePR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
2y agoTLPHTalphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024PR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
2y agoTLPHTalphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
2y agoTLPHTalphera to Participate at A.G.P. Virtual Healthcare ConferencePR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
2y agoTLPHTalphera, Inc. (TLPH) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoTLPHTalphera Announces First Quarter 2024 Financial Results and Provides Corporate UpdatePR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
2y agoTLPHTalphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024PR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
2y agoTLPHTalphera, Inc. (TLPH) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
2y agoTLPHTalphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate UpdatePR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
2y agoTLPHTalphera Announces Reduction in Size of its Board of Directors from Ten to Seven MembersPR NewswireTalphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative...
2y agoTLPHTalphera to Host Fourth Quarter and Full-Year 2023 Financial Results Call and Webcast on March 6, 2024PR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
2y agoTLPHTalphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity OfferingPR NewswireTalphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative...